<DOC>
	<DOCNO>NCT03020719</DOCNO>
	<brief_summary>The purpose randomize , placebo-controlled ( Phase II ) study evaluate effect oral glutathione growth child CF .</brief_summary>
	<brief_title>The Role Oral Glutathione Growth Parameters Children With Cystic Fibrosis</brief_title>
	<detailed_description>prospective , multi-center , randomize , placebocontrolled , double-blind , Phase II clinical trial . Approximately sixty pancreatic insufficient ( PI ) subject CF ≥ 2 &lt; 11 year age , enrol receive either L-Glutathione Reduced ( GSH ) placebo give orally ( tid ) 24 week . Each subject see four study visit : Visit 1 ( Screening ) , Visit 2 ( Baseline/Randomization , Day 0 ) , Visit 3 ( Week 12 ) Visit 4 ( Week 24 ) . At Visit 2 , subject randomize receive either active treatment placebo . Visit 1 2 may combine subject meet eligibility requirement fecal specimen collect prior dose . Safety clinical outcome assess throughout study . Assessment inflammatory bio-markers blood fecal specimen perform Visits 2 4</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Male female ≥ 2 &lt; 11 year age Visit 1 2 . Documentation CF diagnosis evidence follow criterion : Sweat chloride ≥ 60 mEq/L quantitative pilocarpine iontophoresis test ( QPIT ) AND Two wellcharacterized mutation cystic fibrosis transmembrane conductive regulator ( CFTR ) gene 3 . Weightforage 10th 50th percentile Screening ( Visit 1 ) ( use Center Disease Control ( CDC ) reference equation ) 4 . Current chronic use , great 8 week Day 0 , pancreatic enzyme replacement therapy ( PERT ) management pancreatic insufficiency 5 . Written informed consent ( assent applicable ) obtain subject subject 's legal representative ability comply requirement study 6 . Clinically stable significant change health status within 2 week prior Day 0 1 . Intestinal obstruction gastrointestinal surgery within 6 month prior Day 0 2 . History diabetes , Crohn 's disease , celiac disease , bowel resection 3 . Use either oral inhaled GSH Nacetyl cysteine within 4 month prior Screening ( Visit 1 ) 4 . Known hypersensitivity oral glutathione lactose 5 . Initiation new chronic therapy ( e.g. , ibuprofen , hypertonic saline , azithromycin , Pulmozyme , Cayston TOBI Kalydeco , Orkambi , Proton Pump Inhibitor , Histamine H2 Blocker [ PPI/H2blocker ] , Miralax® , PERT , dietary supplementation , probiotic ) within 4 week prior Day 0 6 . Changes amount proprietary dietary supplement formula ( e.g. , Scandishakes , Boost , Pediasure , homemade formula ) give ( oral gastrostomy tube ) within 4 week prior Day 0 7 . Use antibiotic ( oral , IV , inhale ) acute symptom within 2 week prior Day 0 8 . Use oral steroid within 4 week prior Day 0 9 . Active treatment nontuberculous mycobacteria ( NTM ) Day 0 10 . Active treatment allergic bronchopulmonary aspergillosis ( ABPA ) Day 0 11 . Administration investigational drug within 30 day prior Day 0 12 . Sibling receive study drug part study 13 . Presence condition abnormality opinion investigator would compromise safety patient quality data</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Growth Parameters</keyword>
	<keyword>Cystic Fibrosis</keyword>
</DOC>